Cargando…

P666: 1 YEAR RESULTS OF DASATINIB 70MG/DAY VERSUS 100MG/DAY IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE(CML-CP):A PROSPECTIVE RANDOMIZED CONTROLLED STUDY.

Detalles Bibliográficos
Autores principales:	Yu, Dan, Cheng, Hui, Guo, Jingming, Jiang, Rui, Zhang, Youshan, Wan, Chucheng, Qin, Jun, Yuan, Guolin, Chen, Shiming, Yang, Zhuangzhi, Hu, Junbin, Zhang, Yicheng, LI, Weiming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429722/ http://dx.doi.org/10.1097/01.HS9.0000969568.85601.05

Ejemplares similares

COVID-19 in persons with chronic myeloid leukaemia
por: Li, Weiming, et al.
Publicado: (2020)

Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole
por: Schaars, CF, et al.
Publicado: (2006)

Primaquine 30 mg/day versus 15 mg/day during 14 days for the prevention of Plasmodium vivax relapses in adults in French Guiana: a historical comparison
por: Valdes, Audrey, et al.
Publicado: (2018)

The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group
por: Iriyama, Noriyoshi, et al.
Publicado: (2017)

Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy
por: Bonifacio, Massimiliano, et al.
Publicado: (2021)

The Low-Dose (7.5 mg/day) Pioglitazone Therapy
por: Yanai, Hidekatsu, et al.
Publicado: (2017)

Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study
por: Cortes, Jorge E., et al.
Publicado: (2020)

New dosing schedules of dasatinib for CML and adverse event management
por: Wong, Siu-Fun
Publicado: (2009)

Prevalence of gastroduodenal ulcers/erosions in patients taking low-dose aspirin with either 15 mg/day of lansoprazole or 40 mg/day of famotidine: The OITA-GF study 2
por: Tamura, Akira, et al.
Publicado: (2013)

Serum levels of vancomycin: is there a prediction using doses in mg/kg/day or m(2)/day for neonates?
por: Romanelli, Roberta Maia de Castro, et al.
Publicado: (2016)

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients
por: Hochhaus, Andreas, et al.
Publicado: (2013)

The Oral NOAEL of Flurochloridone in Male Wistar Rats in Ninety-Day Subchronic Toxicity Test Was 3mg/kg/day
por: Zhu, Hongyan, et al.
Publicado: (2019)

Clinical Efficacy on Fracture Risk and Safety of 0.5 mg or 1 mg/month Intravenous Ibandronate Versus 2.5 mg/day Oral Risedronate in Patients with Primary Osteoporosis
por: Nakamura, Toshitaka, et al.
Publicado: (2013)

Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia
por: Tamiru, Aschalew, et al.
Publicado: (2021)

Adverse Effects with Finasteride 5 mg/day for Patterned Hair Loss in Premenopausal Women
por: Oliveira-Soares, Rui, et al.
Publicado: (2018)

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib
por: Masiello, David, et al.
Publicado: (2009)

A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer
por: Capdevila, Jaume, et al.
Publicado: (2022)

Treatment-free remission: A new goal for all chronic phase (CP)-CML patients
por: Rea, Delphine
Publicado: (2018)

Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease
por: Ferris, Steven H, et al.
Publicado: (2011)

Finasteride 5 mg/day Treatment of Patterned Hair Loss in Normo-androgenetic Postmenopausal Women
por: Oliveira-Soares, R, et al.
Publicado: (2013)

Prevention of repeated episodes of type 2 reaction of leprosy with the use of thalidomide 100 mg/day()
por: Putinatti, Maria Stella de Mello Ayres, et al.
Publicado: (2014)

Should the dose of tenofovir be reduced to 200–250 mg/day, when combined with protease inhibitors?
por: Hill, Andrew, et al.
Publicado: (2014)

Imatinib Mesylate-Induced Erythema Multiforme: Recurrence after Rechallenge with 200 mg/day Imatinib
por: Lee, Min Kyung, et al.
Publicado: (2015)

Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non–Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis
por: Cho, Byoung Chul, et al.
Publicado: (2023)

The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patients
por: Schubert, Claudia, et al.
Publicado: (2017)

Chronic Myelogenous Leukemia (CML) in the elderly
por: Balducci, Lodovico, et al.
Publicado: (2014)

Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive days.
por: Mulder, P. O., et al.
Publicado: (1990)

Cardiac safety in cluster headache patients using the very high dose of verapamil (≥720 mg/day)
por: Lanteri-Minet, M., et al.
Publicado: (2011)

Effectiveness of betahistine (48 mg/day) in patients with vestibular vertigo during routine practice: The VIRTUOSO study
por: Parfenov, Vladimir A., et al.
Publicado: (2017)

Effect of the number of dose adjustment factors on bleeding risk in patients receiving 30 mg/day edoxaban
por: Takase, Tomoki, et al.
Publicado: (2019)

A Comparison of Cefditoren Pivoxil 8-12 mg/kg/day and Cefditoren Pivoxil 16-20 mg/kg/day in Treatment of Children With Acute Presumed Bacterial Rhinosinusitis: A Prospective, Randomized, Investigator-Blinded, Parallel-Group Study
por: Poachanukoon, Orapan, et al.
Publicado: (2015)

Cobicistat as a Potential Booster of Ponatinib and Dasatinib Exposure in a CML Patient: A Case Study
por: Hofman, Susan, et al.
Publicado: (2023)

Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial
por: Ren, Hong, et al.
Publicado: (2017)

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
por: Hjorth-Hansen, Henrik, et al.
Publicado: (2015)

Many Mg–Mg bonds form the core of the Mg(16)Cp*8Br(4)K cluster anion: the key to a reassessment of the Grignard reagent (GR) formation process?
por: Kruczyński, T., et al.
Publicado: (2016)

Ten Years of Treatment with 400 mg Imatinib per Day in a Case of Advanced Gastrointestinal Stromal Tumor
por: Cameron, Silke, et al.
Publicado: (2011)

Effects on caregiver burden of a donepezil hydrochloride dosage increase to 10 mg/day in patients with Alzheimer’s disease
por: Nakamura, Kazuhito, et al.
Publicado: (2014)

Effect of oral fluconazole 1200 mg/day on QT interval in African adults with HIV-associated cryptococcal meningitis
por: Molloy, Síle F., et al.
Publicado: (2018)

Is Nonmicronized Diosmin 600 mg as Effective as Micronized Diosmin 900 mg plus Hesperidin 100 mg on Chronic Venous Disease Symptoms? Results of a Noninferiority Study
por: Steinbruch, Marcio, et al.
Publicado: (2020)

Comparison of Periochip (chlorhexidine gluconate 2.5 mg) and Arestin (Minocycline hydrochloride 1 mg) in the management of chronic periodontitis
por: Jhinger, Navjot, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1v95g7s6vqkgicoeuf55ghckos